
Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …

Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …

Novartis’ PKC412 (midostaurin) has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …

Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …
Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …

Mumbai-based drug manufacturer Sun Pharma has launched a generic version of Glivec, for the same indications for which the former …

Net sales at Novartis fell by 5% in 2015 – prompting the company to make billion-dollar changes to its business …

Swiss firm Novartis has announced several leadership changes, effective February 1, 2016.In a briefing to present the company’s financial results, …

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

Novartis has won FDA approval for Cosentyx (secukinumab) for the treatment of two new indications – adults with active ankylosing …

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …

Work has begun to transform a 20-acre site that formerly housed Novartis, in West Sussex, into a world renowned centre …